HC Wainwright Cuts Liquidia (NASDAQ:LQDA) Price Target to $58.00

05 Oct 2026, 05:13 by Danessa Lincoln · The Markets Daily

Liquidia (NASDAQ:LQDA – Free Report) had its price objective reduced by HC Wainwright from $130.00 to $58.00 in a report published on Friday, MarketBeat reports. They currently have a buy rating on the stock.

Several other research firms also recently issued reports on LQDA. Citigroup reiterated a “neutral” rating on shares of Liquidia in a research note on Thursday. Wells Fargo & Company reissued an “equal weight” rating and issued a $30.00 price objective (down from $108.00) on shares of Liquidia in a research note on Friday. Oppenheimer set a $75.00 target price on Liquidia in a report on Friday, June 5th. Lifesci Capital cut Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 target price for the company. in a research report on Wednesday, August 12th. Finally, Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Sunday, September 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $83.69.

Read Our Latest Research Report on Liquidia

Liquidia Stock Performance

Shares of NASDAQ LQDA opened at $28.64 on Friday. The business has a 50 day simple moving average of $71.62 and a 200 day simple moving average of $62.21. Liquidia has a 52 week low of $21.91 and a 52 week high of $93.61. The stock has a market cap of $2.56 billion, a price-to-earnings ratio of 20.91 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31.

Liquidia (NASDAQ:LQDA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. Liquidia’s revenue was up 1842.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.49) EPS. On average, research analysts predict that Liquidia will post 2.34 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Roger Jeffs sold 35,249 shares of the firm’s stock in a transaction on Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $2,520,655.99. Following the sale, the chief executive officer owned 1,130,426 shares in the company, valued at approximately $80,836,763.26. This trade represents a 3.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jason Adair sold 73,631 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $69.09, for a total transaction of $5,087,165.79. Following the transaction, the insider directly owned 174,606 shares in the company, valued at $12,063,528.54. This trade represents a 29.66% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 572,519 shares of company stock worth $44,087,514. 25.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Liquidia

Several large investors have recently bought and sold shares of the stock. Globeflex Capital L P acquired a new stake in Liquidia in the 2nd quarter worth $175,000. Nykredit A S acquired a new position in shares of Liquidia during the second quarter valued at about $177,000. Fluent Financial LLC acquired a new position in shares of Liquidia during the second quarter valued at about $287,000. WINTON GROUP Ltd bought a new stake in shares of Liquidia in the second quarter valued at about $335,000. Finally, Fulcrum Equity Management bought a new stake in shares of Liquidia in the second quarter valued at about $399,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

Positive Sentiment: Liquidia’s legal options are not exhausted: an appeal could potentially overturn or narrow the ruling, giving investors a possible path to recovery if Yutrepia’s market opportunity is preserved. Liquidia Stock Crashed 57% in a Day After a Delaware Court Ruling
Positive Sentiment: Despite the litigation setback, Jefferies upgraded LQDA to “strong buy,” while HC Wainwright maintained a “buy” rating and set a $58 price target. These calls indicate that some analysts believe the selloff has overstated the long-term damage or that an appeal could succeed.
Neutral Sentiment: HC Wainwright cut its target from $130 to $58, and Needham reduced its target from $110 to $72, although both retained “buy” ratings. The sharply lower targets reflect materially higher legal and commercialization risk even among bullish analysts.
Negative Sentiment: BTIG downgraded Liquidia to “neutral,” and Wells Fargo added to the analyst downgrades following the patent ruling. Analysts cited uncertainty over Yutrepia’s PH-ILD indication and the possibility that UTHR’s patent victory could limit Liquidia’s addressable market. Liquidia extends losses as Wells Fargo adds to downgrades
Negative Sentiment: The court setback triggered a severe selloff, leaving LQDA on track for its worst week on record as investors reassessed Yutrepia’s revenue potential and Liquidia’s competitive position. The stock’s unusually heavy trading volume underscores the market’s heightened uncertainty. LQDA Stock On Track For Worst Week Ever

Liquidia Company Profile

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.